Replay available
OneSource Specialty Pharma (NSE:ONESOURCE) Q1 2027 Earnings Call
OneSource Specialty Pharma (NSE:ONESOURCE) Q1 2027 earnings call, held 2026-07-25. Watch the replay and read the transcript on 6ix.

- Company
- OneSource Specialty Pharma Limited (NSE:ONESOURCE)
- Period
- Q1 2027 earnings call
- Date
- Sat, Jul 25, 2026, 5:32 AM ET
- Replay
- Watch the replay on this page · 58 min
On 6ix: 6ix.com/event/onesource-specialty-pharma-limited-onesource-q1-2027-earnings-call
Replay
Transcript
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Ladies and gentlemen, good day, and welcome to ONESOURCE Specialty Pharma Limited Q1 FY 'twenty seven Earnings Conference Call. As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this conference is being recorded. I now hand the conference over to Abhishek. Thank you, and over to you, Mr. Abhishek. Thank you, Renju, and thank you all for joining us today for the earnings conference call of Onesource Specialty Pharma Limited for Q1 FY twenty twenty seven. We are pleased to have with us Neeraj, CEO and MD and Anurag, CFO of the company, who will walk you through the key business and financial highlights for the quarter. I trust you have had the portion to review our results release and the investor presentation, both of which are available on our website as well as our stock exchange website.
0:55 The transcript for this call will be posted on the company's website within the next week. Please note that today's discussion may contain forward looking statements, which should be viewed in context to the risks inherent in our business. Should you have any further questions after this call, our Investor Relations team will be happy to assist you. I now hand over the call to Neeraj for his opening remarks. Thank you, Abhishek, and a very warm welcome to everyone joining us today on this Saturday morning. I really appreciate your time and happy to share the Q1 results with you. So the quarter has been fairly strong for us. Revenues have are at million and have grown 37% year on year. And these are yet driven by the semi gluteat commercial launch, new MSA contract and also new customer wins across our various businesses.
1:55 EBITDA has also come in at INR1233 million, which has been up significantly 39% year on year as well as sequentially 34% versus last quarter and which has been in line when we have said last time that we will be showing a sequential quarter on quarter growth. The quarter also marks really a meaningful step up in our CEMA commercialization in Canada, which as you all know, is the largest off patent market available today in the world. Currently, all three approvals which are there in the market are with us. And in fact, two of our partners who you know have already launched in the market.
2:42 Even in India, which is other significant market open available, many of our customers launched on day one. And as of June 26, more than 40% of the generic pens market sold in India are manufactured at our site. In fact, I also want to say that despite the temporary disruption in supplies, which has been announced by Doctor. Radhis, our available capacities are full. Thanks to really our customer base, which spans across markets and across companies. And this has really helped us pull the demand while the DRL supplies resume. And in fact, at the same time, as we have announced earlier, you well know that our first phase of the INR 100,000,000 CapEx, which we have put investment, which we have put in our CapEx is now reaching fruition with our second cartridge line being set for commercialization in this quarter.
3:48 This line, as you know, will double our number of sterile days available for production. And this additional capacity will not only support supply to DRL as and when they resume, but also to multiple countries as which are due to open in the remaining part of the year. But also, this will help expand our customer base. We have been saying we have not been able to add new customers because of supply gap. Now we with this new supply available, we would be adding customers. In fact, the process has already begun with our first new GLP customer adding coming on board last quarter. Within FY 'twenty seven, we will have yet another line which will get installed, which will really which will make us really one of the very few global CDMOs offering this level of capacity and having complete end to end capabilities, including assembly, packaging, the works in drug device combination.
4:58 In fact, the strength of our complex peptide development and drug device capability was also demonstrated once again when with two of our customers successfully getting the first to file status in U. S. With tirzepatide, which is a significant achievement for the team, which has worked very hard on it. At the same time, our second key future growth pillar of Biologics saw us adding yet another marquee global biotech major. Our partnership with Formicon really brings together their biosimilar development expertise and our integrated manufacturing capabilities really to expand access, which is what is really key, access to high quality, affordable biologics for really global patients. It also speaks very well on how India and Us specifically are emerging as a trusted partner for the global biologic development and manufacturing.
6:03 Our pipeline, I think this is what it's important for us to say that the pipeline continues to be built with our RFP funnel today is almost 4x of what it was just over a year ago. And this spans across innovators, biosimilars as well as animal health companies. Now this is strongest ever and also very significant because, as you know, biologics is a long gestation business, but at the same time, also very sticky. And thus, this business will be a significant contributor to our growth even beyond FY 'twenty eight. Also in our across our base business, injectables of Gelagene, we see a very strong customer engagement and expand across our businesses.
6:54 We have had nine new launches. During the quarter, we added six new logos, which is really expanding our already wide customer base. One thing which we've always been proud of and it gets reiterated in this quarter that our compliance track record remains exemplary. We had 12 successful inspections this quarter across regulatory inspections and customer audits, including two surprise FDA audits across two of our sites. So really, really proud of our achievement there. So in nutshell, I just want to say that it was a strong start to the year. The commercial momentum in our DTC business, which is supported by our capacity, new capacity coming online and a very strong build out in our Biologics.
7:45 With all this, we really remain confident and are happy to reiterate our FY 'twenty eight outlook of INR 400,000,000 organic revenue as well as EBITDA margins of 40%. I really thank you once again and would be happy to take questions along with our CFO, Anurag. Thank you. We will now begin the question and answer session. The first question comes from the line of Rupesh Tatya with Longevity Longevity Partners. Please go ahead.
8:42 Yeah. Hi. Hi, Niraj. Thank you for opportunity, and congratulations on good steps. I I have several questions. Let's see how many I can get in. So first question, Niraj, is on soft gelatin capsules. The capacity went from 800,000,000 to 2,400,000,000. It it it has been quite some time now. The the the business was around $505.50 per all kind of revenue. I thought by now, it was already, you know, $809,100 per hour, and maybe 1,200 per hour next year. You don't give the split, but it doesn't seem like that business has grown. So what is the issue there? And the corollary to that is the broader group companies are facing issues in ibuprofen. So is that impacting this business? Rupesh, thank you for your question. So I think we have been very clear in saying that we are our new capacity has come on board.
9:37 Softgel is a significant business with very long legacy. We are among few companies with such deep expertise in development and manufacturing. And with the capacity we have put up, we are certainly among the top four or five companies when it comes to pharmaceuticals of Gelatin capacity. Having said that, you know that this business under strike was primarily focused on captive IP led products. And with this new capacity, which we have added, it has we have started offering CDMO services. And there is a significant amount of interest in this considering some of the largest players in Europe have had various challenges either because of acquisition or otherwise.
10:31 And this interest, it takes finite amount of time for tech transfers to happen from other companies, other sites to our site. The process is on. In fact, we see our capacity, which was added to be completely taken over the next twelve to fifteen odd months. And I also want to share with you that because we are completely we have no possibility to increase capacity further in the current site, we have already initiated a process of starting a greenfield. And over the next quarter or so, we'll be sharing with you what the update on that. But we are very confident of our soft gelatin business, and we continue to add customers. It will be a strong driver of our growth in the foreseeable FY twenty twenty guidance, but also beyond that period.
11:41 That's encouraging. And also any update on the margin improvement program we had for Sterifcience, that also I think we haven't discussed that for a while now. So in the injectable business, have as we have said, it's a focused we have our injectable business is very, very focused on scarcity play, whereas you know that we either go for products which are very which require dedicated manufacturing like penicillins. You know we have one of the few FDA approved penicillin plants anywhere in the world with an absolutely excellent compliance track record, thanks to which we have a significant share of penicillins in The U. S.
12:32 And the products which are perpetually in FDA shortage list. Now which is so it's a focused portfolio. It's not a huge portfolio, it's a focused portfolio. And also our customers there are those who really value sustained long term continued supplies over low prices. So that's the therefore, it's our plan is very clear. What we have also said that we are adding new capability in the injectable business, which is around prefilled syringes, and we are also significantly adding to our lyophilization capacities. And as we had said earlier, in fact, this first half itself, we will be taking a shutdown on our one of our trial injectable sites basically to add this capacity. So you will see this addition will be a significant contributor to our FY 'twenty eight numbers.
13:36 Thank you. Mr. Tatia, please rejoin the queue for more questions. Next question comes from the line of Abdul Qadar Purnwala from ICIC Securities. Just taking the conversation ahead from the previous participant. So you mentioned about the plant shutdown on the injectable side. So did that have any impact in this quarter as well? Or that's something you plan to do in the second quarter? So, Abdul, it will be starting this quarter. Q2 will be the quarter in which the shutdown will be taken, and it will last between this quarter and the next quarter.
14:27 Okay. Sure. Understood. And sir, if I have to just understand your sequential performance. So if I look at in the U. S. Dollar terms, so your revenues were quite identical, but the margin in this quarter, I know, has improved significantly. So anything to highlight here both on a mix point of view as well as on your overage, if you could help us understand the numbers a little better? Yes. So I can definitely can say, Abdul, that it's basically the mix which is driving this. As you see, there's a significant improvement in margins, which is primarily coming from higher contribution from the drug device combination business, which I already said in my opening remarks.
15:22 And also, know, right, traditionally, it's always the case that our base business, Softgel, as Injectables, is primarily H2 heavy. So the contribution from Softgel obviously starts more towards the second half of the year when the flu seasons pick up, etcetera. So primarily coming from that, the margin gets driven up. That's why the mix between revenue as well as margin. Got it. Got it. And so next question is on one of your customers have been talked about shutting down their API manufacturing, and they have been talking about, you know, some kind of a delay in terms of the market reentry.
16:09 So, you know, I understand we would have many customers to cater to, but, are you assessing some kind of a temporary disruption in the near term because of that customer pulling out for a temporary period? So I think, Abdul, as you rightly mentioned, I alluded to it also in my opening remarks that the benefit of having pretty diverse customer base, We have more customers in Canada. We have customers all across. We have customers with commercial launches. We have customers with MSAs. So thanks to all these, we are able to actually pull demand into this quarter, therefore, which is what the time line, which Doctor. Reddy's have shared publicly.
17:05 And therefore, thanks to that, we have had we don't anticipate any impact on that on our supplies. As said, we don't have any reasons to not believe what Doctor. Reddy has said in terms of resumption. And therefore, for us, we are very clear that we have enough capacities. All our capacities right now are full, thanks to multiple customers. And at the same time, you know that we are adding new capacities starting this quarter itself. And as and when Doctor. Reddy's resume, our capacities will be sufficient to meet their demand as well as demand for other customers. Okay. Okay. So when we talk about our capacity addition and customer demand, so just directionally, if I have to understand, what is the kind of order book visibility do you have today? I know we are reaffirming our FY 'twenty eight guidance.
18:08 But achieving that $400,000,000 kind of revenue, do we have that kind of an order book visibility today? So I can tell you, Abdul, that short answer to your question is yes. The little bit longer answer is that we have got multiple pillars of that business, right? So yes, indeed, drug device combination is going to be one of very important contributors. And there, as you know, that apart from the customers who already are there and we in Canada, for example, three on three, even if Doctor. Adi has its temporary disruption, still three on three approvals in Canada are with us.
18:56 India, we are today almost 40% of the market generic brands we are supplying. Multiple new markets opening up in the next six, eight, nine months and our customers being present across all those markets. So keeping all those in mind, we the drug device combination business has a very significant traction and that order book is very clear. When I come to our other key pillar, which I have already mentioned, our Biologics business, very significant traction. We have already announced new contracts, new customers coming on board. We have a very strong funnel there, which is going to be converting over the next coming quarters.
19:51 Our base business, as I mentioned to you, saw gelatine new customers getting added, new the capacity available getting filled, the injectables, which I just mentioned to you, while we take shutdown of few months in this year, but that is entirely going to be available, the new capacity and the new capability available for the full year FY 'twenty eight. So each of our business offerings is going to be contributing to our FY 2020 guidance what we have given. Got it. Thank you and all the best. Thank you. Thank you. Next question comes from the line of Girish Bhakaroo with Albumet.
20:43 Please go ahead. Thanks. Anita, just trying to assess line two utilization. I mean, can the customers from line one be added to line two? And, I mean, in case, let's say, Equatex in this case requires more capacities. I mean, who takes that call? Is it the customer or you can shift given the highlights as in Line two? Yes. Thank you, Girish, for the question. So the answer to your question is straight that the lines what we have added, when even when we had started this program of adding capacity, the idea was line all lines should be able to cater to all our customers.
21:30 And that is exactly how we have planned. The capacities are fungible across customers, across products. So the based upon all the work with the teams have done, both our teams and our customer teams, we will be moving existing customers on the new line as well. In fact, customers will be serviced from both the lines. And as we have said, are very working very closely with the customers to actually increase the batch sizes as well from mostly 200 liters to 500 liter, which would be of immense benefit to our customers as well as for us to be able to bring a significant increase in the output from the same sterile days. So yes, all our in fact, one line is coming in online this quarter, then another line will also be ready within this current financial year. So all these customers would be able to use.
22:39 Understood. And this batch size variation, let's say, does it need to be resubmitted to authorities for approval or can this be done without any paper? Yes. So our understanding, Girish, along with our customers is that it should be possible for most geographies. It will depend market to market. But in most geographies, it should be possible to increase the batch size in a pretty quick time period. Okay. And can you share, I mean, how many CSAs are right now on Line one? And how many you anticipate on Line two, say end of the year? I think that may not be usually relevant metric for you. I think what you need to understand is that the customers who we have are fairly, as I mentioned, three zero three in Canada. You have Doctor. Eddy has told you some other names also, which is on which are going to be getting added.
23:45 And these and we have got customers who are also new customers we have added from MSA point of view. So the lines, the idea of adding capacity is the new lines is that we should have the flexibility to be moving from one line to another, customer A to customer B, so that not only we are able to meet the demand of all the customers, but to be able to get right customers and give them the time lines which they really need to reach the market. So therefore, I think the right metric for you is that we have sufficient customers and sufficient customer demand on both the lines, which will be available for this year.
24:35 Understood. But I'm just thinking more from, let's say, given you have these extra sterility now available, you would rather have more mix of commercial agreements, right? So is there a significant mix change we will see going forward between what is MSA versus CSA? So we the lines are driven by the CSA. It's that we have always said that the mix of the company is going to be driven by significantly more CSA. The whole idea is that the capacity has been constrained till now, right? We have been very open about it that we have more demand than we are able to cater.
25:24 But now with the new line coming in, the capacity has there is more capacity, significantly more capacity available. And thanks to that, we are absolutely able to onboard new customers, which also in the previous calls, I have mentioned that we are not able to add new customers because of this capacity constraint. Now that we have clear visibility of the new capacity getting added, we have initiated adding new customers. We already had a new customer coming in last quarter, and that is what is key for us. But just to in terms of the mix, it will be significantly more MSAs as I said significantly more commercial sales than MSAs.
26:13 Very happy to hear. Thank you so much. It's very helpful. Thank you. Next question comes from the line of Gautamy Agarwal, an individual investor. Please go ahead. Hello, sir. So we know about your FY twenty eight guidance of $160,000,000 US dollars EBITDA. But can you highlight few initiatives you are taking for a longer term, which is beyond FY twenty eight? So if we model FY twenty nine thirty for ONESOURCE, do we think of growth trajectory longer term on '28 basis remain intact or otherwise?
26:58 Can you give some clarity on that bit? Yes. Thank you for asking. One clear answer for you is that, yes, our EBITDA trajectory will continue to go upward beyond FY 2028. And this is going to be dependent on all our modalities, which all our service offerings. I already mentioned today that our Biologics business, which is a great contributor to going to be on this growth simply because while our RFPs have seen significantly significant growth over this last twelve, fifteen months, Biologics takes time to establish, but it sticks on much longer.
27:57 And the kind of customers we are adding across the segments, whether it is animal health, biosimilars, innovators, this is going to be a very long legs of our business because many of these customers, the commercial revenues will start coming in FY 'twenty nine onwards. So right now, over the next two years, most of these will be the development MSA revenues and then getting converted beyond. And thanks to the visibility which we have on our customers, we are also going to be taking some of the capacity expansion because we see our current Biologics capacity will require expansion. So we are going to be expanding both the mammalian as well as microbial capacity.
28:49 So this will be a very strong driver of our growth beyond FY 'twenty eight. Also, our Softgel team business, which we just spoke about, that with the capacities getting filled, this will again be driving growth. For us, The new capability is being added in injectable business. Those will be significantly beyond FY 2028 for us. And then we should certainly not forget that the drug device business has got also very long lag. The reason we are adding all these capacities is because right now, up to FY 2028 guidance, we are only dependent on the emerging markets apart from Canada, Emerging markets volumes.
29:48 However, from 2930 onwards, Europe opens up. And then, of course, U. S. Opens up with all our FTF customers. So again, reiterating all the businesses, the drug device combination, biologics as well as the softgel and injectables will be driving our business beyond FY 2028. Okay. Okay, sir. Thank you. That perfectly answers my question. Thank you. Thank you. Thank you. Next question comes from the line of Pranav Chawla with GM AMC. Please go ahead. Congratulations, sir, for the good set of results. I just want to understand on the biologics, I've announced a couple of contracts.
30:38 Can you give some color on those contracts? When will they begin to contribute? And to begin, how large can these contracts become for us? And do you plan to add any dedicated capacity for these? Yes. Pranav, I think your voice was breaking, but I understood the questions. So you see, as we have been saying, right, it's we are really focused on expanding the Biologics business, and that's what we the new wins are really helpful. We announced in the last quarter that one of our pillars, which is Animal Health business, we were able to get additional contract.
31:26 Then we are, in this quarter, another pillar of our business, which is biosimilars. We added a very, very important large global player for Micron in as a customer. And last year, we had said we had another European biotech company, which was a customer. So these are all going to be staying with us for long term. The reason they are coming to us is simply because with the change in biosimilar guidelines, as you know, in both U. S. And in Europe, there requirement is of agile partners of manufacturing who are quick to help companies reach the market and remain competitive over a very long time. And that is what we in ONESOURCE offer to these customers.
32:26 So these companies have got a very strong pipeline. And partnering with them will give us access is giving us access to that pipeline. And we see them as significant contributors in our growth journey. As I said, beyond FY 2028 because while right now we will do MSAs for them, but the commercialization for these companies will be FY 'twenty nine and beyond. To your question on the capacity, as I mentioned, yes, based upon the visibility, pipeline visibility we have today, we do see the need to go beyond our existing capacity in both mammalian and microbial.
33:15 And as and when, know, we have recently are the process of completing the CapEx in the drug device combination. So therefore, we would not shy away from adding capacity as and when it is required to be able to service not only the demand of these existing customers, but also the customers who are in the pipeline. Sir, and one last thing from my end. So within the biologic within biologics, where do you stand in the value chain for a customer? Do we also do R and D or we are primary CMO partner? Just trying to get some color on your biologics business.
34:02 Yeah. Thank you. Sure. So we are our value proposition to our customers is that we are very among very few completely integrated drug substance and drug product player in Biologics. We actually can take right from a gene to the final product which the patient uses. So we provide entire value chain from scaling up to the drug substance and not once you scale up the drug substance to be able to fill it, fill finish in the same site and to be able to pack it, assemble it in an auto injector or in a pen injector and give the final pack which the patient opens at home. So the full end to end value chain is our proposition.
34:58 We have a very strong significant R and D team, development team, which is able to offer services across the board. So that's the value we offer to our customers. Sir, and one last question, if I may be able to squeeze in. So from what we understand, a lot of domestic players are also trying to get into the CDMO piece for Biologics. Obviously, our backward integration or being able to be part of the whole supply chain does help. Do you see this as a material risk going forward for our Biologics offering? See, I can tell you there is a significant increase in demand for CDMO services globally, especially in Biologics.
35:51 Today, Biologics and Drug Device Combination are two of the fastest growing segments in CDMO globally. Thanks to this demand, more than 50% of all drug discovery today is biologics. With all the change in guidelines, biosimilar access is just going to get a huge boost. With all this demand coming in, India today has got a very, very insignificant share of this. So with the demand coming in, with the challenge, the need to push out of China, all this put together means that the share which will come to India will be sufficient.
36:40 There will be enough demand for all the new capacity coming in. Remember, the capacity which is available in India is still a very small fraction of what is available in countries like South Korea, for example. So I see this as an opportunity for companies coming to India and especially to ONESOURCE because we are among a very, very small group of CDMOs offering integrated drug substance and drug product in the same site. Got it. Thank you so much, sir, for your answers. That is all from me. Thank you. Next question comes from the line of Ritika Agarwal with ValleyQuest.
37:29 Please go ahead. Hi, sir. Thank you for taking my questions. First question is, what we understood is you're expanding capacity in almost all of these segments, which is DDC, injectables, softgel and biologics maybe going ahead. Could you help us understand what is the capacity utilization currently for each of these segments? So Ritika, as we mentioned, the reason for our investing significant amount in adding capacity in truck device combination was basically because we didn't have capacity to service the demand we have. So you can imagine the utilization of all our current capacity there is complete.
38:26 And similar function, I can tell you for injectables because the reason we are adding so much lyophilization capacity is that our the demand today is higher than the capacity. Soft gelatin, the reason we decided to add capacity because till now, under strides, the entire business was captive. It was in house development meant for sales by Strides front end. But now it has come as it comes to ONESOURCE, we are able to really offer this expertise, both in development and in manufacturing to a very wide group of customers, which is what the demand is.
39:14 But at the same time, it will there, we need to keep capacity to service new customers. As a CDMO, please understand, we have to have capacity first and then add customers because you can't we can't start building capacity when we have the customers because that's the whole model of CDMOs that we build capacity, build capability and then go and sell. So it's going to be a combination of using the capacity to serve existing customers and then keeping spare capacity to be able to onboard new customers. Got it, sir. So we should understand DDC and injectables are running probably at the peak capacity, while soft gelatin, we are adding capacity to serve the CDMO demand.
40:10 But apart from that, of the current 2,000,000,000 kind of capacity, what should be our current capacity utilization for Softgel? Can you just on Softgel, your question is that what kind of capacity utilization? Yes, yes, on the current capacity. So remember that, as I said, right, it's a we increase the capacity to basically cater to CDMO customers. And CDMO customers basically are the ones who would do the tech transfer from their existing mass locate site. And as we speak, right now, that's the process which is underway, where customers are doing the tech transfer.
41:00 And at the same time, so as I mentioned, we will, over the next two years or so, completing the capacity utilization of this site. And beyond that, we would need a greenfield site to be added. So that's what we will be doing. Even on our drug device combination, what we have added while our capacities on cartridge filling are complete. Remember, we also have prefilled syringes capability capacity, which still is most of it is available as we add new customers in that specific area. So both, some capacity is fully utilized, lot of capacity is still available for us to be able to add new customers and add to our growth to FY 'twenty eight and beyond FY 'twenty eight.
41:56 Sure. Last question, what is the kind of CapEx that we are looking for this year and the next year, including all the capacity expansions that we are talking about? So we already said, right, that we are roughly last year, we mentioned we had taken about 100,000,000 CapEx to be invested across sites, most of it coming to drug device combination. As we sit today, almost 80% of that CapEx has been committed. So that's where we are looking at. As and when we do the capacity expansion in Biologics, we will see what additional CapEx will be required, but it be certainly significantly lower than what we have invested in or what we are investing in drug device combination.
42:53 So for this year, no significant CapEx is what we are looking at? What would be the CapEx number, which is the balance 20% of the $100,000,000 and anything additional apart from that? So as of now, this is what we have clear visibility on. As I mentioned, as and when we expand our biologics, we would be needing beyond this number, but it will be significantly lower amount than what we have invested in DDC. Thank you. Mr. Agarwal, please return the queue for more questions. Next question comes from the line of Anish Jubbalia with Credit Capital. Please go ahead. Hi, sir. Good morning and thank you for the opportunity.
43:40 Sir, my first question is if you can give some comments on how our customers are seeing the response for the generic versions of the weight loss that are being introducing our key markets like Canada and India, that would be helpful because they have been recently launched. So just to know how the response has We have mentioned earlier in previous calls as well. The constraint in this market has been supply not demand. In fact, the demand has been significantly outpacing supply both in the market where the brand was present launching.
44:39 So what Erics have essentially done is to provide access to the latent demand, which has been there. So if you see all the markets, India, for example, which is a completely out of pocket market, you see how within a year, we were at less 2000p in a month going up to now 150,000,160,000 pens. So all this and this is you see still a significant constraint in supplies. Same, Canada is very early yet to say. But I think there is a clear trajectory because the demand of the patient number is going up and availability as well as the price delta versus the brand will all drive significant demand. And that's what our customers are showing.
45:41 All our customers have their forecasts remain as robust as Okay, sir. Sir, am I audible? That's clear to hear. So my second question is, basically, sir, we have one line coming up in this quarter. So are there any risk that we have to monitor in terms of scaling up of those lines? If you can just speak a little bit about are there any challenges or like how they will be scaling up over the next few quarters? And also if you can comment like in this year, we are only looking at one line or all the four lines will be in place, which we are targeting.
46:29 Understood. Yes. See, as I mentioned, till now, we have been really struggling to meet the demand because of one line was heavily overbooked. And the reason for us to add new line, not new line, but new lines is because we have a very clear visibility on the demand. So the current the new line, which is coming onboard, we are absolutely sure of getting that capacity filled. And the third line will also be ready the current financial year.
47:15 In fact, you know that by three lines will be available fully for FY 'twenty eight, but later in the FY 'twenty eight, we are going to be having a fourth line as well because, as I said, not only we are bothered about filling all the demand over the next two years, but beyond with a lot of new markets opening up from 'twenty eight, 'twenty nine onwards, we will have sufficient capacity to cover all our customers, who you know are literally the who's who of the global generic market. We will be able to service all the demand coming beyond the emerging markets as well.
48:06 Okay, sir. Thank you for your time and wishing you all the very best to achieve your guidance. Thank you. Thank you. Next question comes from the line of Malik Warrior with three sixty one Capital. Yes. Hi, sir. I hope I'm audible. Thank you for the opportunity. So my question is you secured your first oncology softgel NDA with a top 10 US generic. So has the customer launched the product? And if yes, how should we think about the revenue ramp up as I think there's only one supplier other than you? Thank you, Malik. Yes, indeed, the product, which is our first oncology product going into the market.
48:57 It is expected the customer is expected to launch it in the current quarter. What this product is really giving us, as said, the first ever oncology unique because it's a brand, it's an NDA and not an NDA. And it there is only one other supplier. As you mentioned, it gives us the capability basically, we showcase the capability of ONESOURCE in this specialized oral technology. In terms of revenue, I can only say that it's a small market. So we don't really see a very significant contribution to the revenue in near term.
49:49 Thank you, sir. Thank you. Next question comes from the line of Nitin Agarwal with DAM Capital. Please go ahead. Hi. Thanks for taking the question. You had just started up. Some of these things have been asked earlier that we're trying to get a little more color on this. So on the sterile on Line one, how would you assess, like, for example, what we've done in Q1 in Line one? Have we achieved because the line is running to capacity. But from an EBITDA perspective, is it the optimal contribution from the sterile date, which Line one has, that you've achieved in Q1? Yes, Anastin, thanks. See, as we have said, right, that we look at one line at about roughly two twenty five odd days, the sterile days available. And based upon the per day realization for us, I would say that quarter one, we had reached fairly the full contribution, which is there per line.
50:47 And that's how that covers the last quarter. And once the new line gets fully functional from next quarter onwards, we will start seeing the same contribution of trial days. But as you know, each line doubles as trial days. So from two twenty five million dollars on a full year basis, the next line will provide us another $225,000,000 And when the third comes in, another $225,000,000 So let's say, for FY 'twenty eight, we'll have $475,000,000 trial days available to us. Which I get. My question here is that from the delta that you're looking at, right, from the two lines coming through, there still is a lot of gap between what we've delivered in Q1 to versus what we expect to achieve in F twenty twenty eight with the two sterile days tripling, right? So my only question was, have we achieved the optimal EBITDA contribution from Line one in Q1?
51:50 So I would just say, from a revenue perspective, yes. But remember also that we have been saying that with all this new capacity coming in, the OpEx has to be upfronted. So while the new line revenue will be coming in as the lines get installed, but the OpEx is there today already. So as new lines will come in, the OpEx leverage will play in more. So the real contribution from those lines will come when all the lines are in place because very limited incremental OpEx because most of the OpEx we have upfronted on these lines already. Okay. So the revenue is largely sort of reflective of the peak utilization of one of the profitability is not because there's a lot of costs from subsequent phases already up... Up fronted in the in the expenses.
52:45 Indeed. Absolutely. Okay. Okay. Thank you so much. Thank you. Next question comes from the line of Gaurav Shukla with Finvesta. Please go ahead, sir. Ma'am, what is that, sir? Yes, indeed, you Sir, congratulations for a good set of numbers, and thank you for giving me opportunity. Sir, my question is that how we see FY '27 and FY '28 in this scenario? What is the effect of geopolitical geopolitical issues on this? And new latest announcement of the president of America wrote tariff on Genvik after two years. How will you see some comments there? Yes.
53:38 Sure. See, the geopolitics is in a flux, no doubt about that, especially what is happening in The Middle East is in nobody's interest. So for us, also, typically, it has impacted in terms of the freight challenges with Suez and Strait Of Hormuz being closed. All the shipments from India to Europe and to U. S. Have to take a much longer route across the Cape Of Good Hope, which actually really increases the shipment time. But not only that, it also is leading to a constraint in the supply of containers because the turnaround is reduced.
54:32 So that is certainly not in anybody's interest. It also increases the cost of freight. But the benefit, let's say, how would I say, as a CDMO, our impact is fairly muted there simply because we have all ex works contracts. So the any additional time and cost is actually picked up by our customers. So but it is not in anybody's interest because we really hope the things calm down quickly. On the impacts impact of the announcement from U. S. Administration a couple of days back, as we have all seen, right, that the number of changes and back downs done by this administration, we see exactly the same story to pan out.
55:38 It's too early to say, but we don't see this to be causing any long term harm to us or to our customers. Thank you. Mr. Shukla, please rejoin the queue for more questions. Next question comes from the line of Pat Soda with Treneto Asset Managers. Please go ahead. So first of all, good morning, and thank you for the opportunity. Almost my questions are covered, but I need just more clarity on the FY '27. Like, what are the key milestone investors should monitor over the remaining three quarters of FY twenty twenty seven to assess whether the company is on track to achieve FY twenty twenty eight objectives?
56:27 I think as we have said that right, right now we have got fairly strong visibility on our order book and on our capacity utilization. So therefore, the first thing which we were which we have been tracking is the addition of the capacity, which, as I mentioned, we will be adding new capacity starting this quarter. And our next capacity expansion will happen towards end of the year, as again, we have mentioned, which is a key thing for you to see. You will also start seeing once the impact of new line getting added and the revenues ramping up accordingly in the second half, as also we have mentioned.
57:23 Other than that, I mean, that's the operating leverage. And of course, you will see this as a sequential quarter on quarter improvement in our revenue and in EBITDA. Got it. Got it. Thank you so much and all the best to you guys. You. Ladies and gentlemen, that was the last question for today. We have reached the end of question and answer session. I now hand the conference over to the management for closing comments. Yes. Thank you. Thank you for all the questions. Thank you for the interest. And thank you once again for spending your Saturday morning with us. Thank you very much. Thank you. On behalf of ONESOURCE Specialty Pharma Limited, that concludes this conference. Thank you for joining us. You may now disconnect your line.
Follow OneSource Specialty Pharma Limited into a list and get an email when it puts out news.
Latest news releases
- NSE:ONESOURCE — Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 30, 2026, titled "OneSource Receives USFDA EIR with VAI Classification, Marking… · Fri, Oct 30, 2026
- NSE:ONESOURCE — Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA… · Tue, Oct 27, 2026